- Previous Close
490.55 - Open
489.75 - Bid 486.65 x --
- Ask 488.45 x --
- Day's Range
486.10 - 489.75 - 52 Week Range
440.30 - 573.30 - Volume
0 - Avg. Volume
1 - Market Cap (intraday)
187.88B - Beta (5Y Monthly) 0.79
- PE Ratio (TTM)
32.06 - EPS (TTM)
15.21 - Earnings Date Jan 31, 2025 - Feb 5, 2025
- Forward Dividend & Yield 1.45 (0.30%)
- Ex-Dividend Date Dec 13, 2024
- 1y Target Est
--
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. It has a collaboration agreement with Mainz Biomed N.V. for the development of colorectal cancer screening product. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
www.thermofisher.com122,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: TMOF.VI
View MorePerformance Overview: TMOF.VI
Trailing total returns as of 11/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TMOF.VI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TMOF.VI
View MoreValuation Measures
Market Cap
187.88B
Enterprise Value
215.33B
Trailing P/E
32.03
Forward P/E
21.64
PEG Ratio (5yr expected)
1.95
Price/Sales (ttm)
4.63
Price/Book (mrq)
3.99
Enterprise Value/Revenue
5.31
Enterprise Value/EBITDA
19.55
Financial Highlights
Profitability and Income Statement
Profit Margin
14.48%
Return on Assets (ttm)
4.67%
Return on Equity (ttm)
12.94%
Revenue (ttm)
42.37B
Net Income Avi to Common (ttm)
6.14B
Diluted EPS (ttm)
15.21
Balance Sheet and Cash Flow
Total Cash (mrq)
6.65B
Total Debt/Equity (mrq)
72.33%
Levered Free Cash Flow (ttm)
6.78B